Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBC

Condition:   Liver Cirrhosis, Biliary Interventions:   Drug: Obeticholic acid;   Drug: Bezafibrate 200 MG;   Drug: OCA Placebo;   Drug: Bezafibrate 200 mg Placebo;   Drug: Bezafibrate 400 MG;   Drug: Bezafibrate 400 mg Placebo Sponsor:   Intercept Pharmaceuticals Recruiting

Source: ClinicalTrials.gov - October 20, 2020 Category: Research Source Type: clinical trials